Evidence map›Paper›PMID 41765344›Full record

ReviewBiological psychiatry2026

GluN2D NMDA Receptors: Bridging Physiology and Pathology.

Kishore Kumar S Narasimhan, Shashank M Dravid

Abstract readReview
In one paragraph

Review in Biological psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kishore Kumar S NarasimhanDepartment of Psychiatry and Behavioral Sciences, Texas A&M Health Sciences Center, College of Medicine, Texas A&M University, College Station, Texas.
Shashank M DravidDepartment of Psychiatry and Behavioral Sciences, Texas A&M Health Sciences Center, College of Medicine, Texas A&M University, College Station, Texas. Electronic address: smdravid@tamu.edu.

Funding

Trans-synaptic signaling complex in amygdala pain mechanismsR01NS118731 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI DRAVID, SHASHANK MANOHAR, NEUGEBAUER, VOLKER · 2020 to 2024
$2.7M
Striatal Trans-Synaptic Signaling Mechanism in ParkinsonismR01NS133338 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI Hong-Yuan Chu, Shashank Manohar Dravid · 2024 to 2026
$2.0M
Function of glutamate delta-1 receptorR01MH116003 · NIMH · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI DRAVID, SHASHANK MANOHAR · 2018 to 2022
$1.9M
Structure-Function and Signaling of Glutamate Delta 1 in Pain MechanismR21NS132590 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI DRAVID, SHASHANK MANOHAR · 2023 to 2023
$404k
NIMH NIH HHS R01 MH116003NINDS NIH HHS R01 NS118731NINDS NIH HHS R01 NS133338NINDS NIH HHS R21 NS132590
6 · The paper itself

Abstract

NMDA receptors (NMDARs) are pivotal mediators of excitatory neurotransmission and play crucial roles in normal brain development, synaptic plasticity, and higher-order cognitive functions such as learning and memory. Their involvement in such diverse physiological processes arises from the complex regulation of synaptic and neuronal activity, primarily conferred by subunit heterogeneity. The combination of different GluN2 subunits, each with distinct spatiotemporal expression patterns, localization within neuronal circuits, and unique biophysical and pharmacological properties, enables NMDARs to finely tune synaptic responses across various brain regions and developmental stages. Among these, the GluN2D subunit has remained relatively understudied compared with the extensively characterized GluN2A and GluN2B. Nonetheless, recent advances have brought renewed attention to their specialized roles. GluN2D is broadly expressed during embryonic and early postnatal development, but its expression becomes more spatially restricted in the adult brain, where it is predominantly found in subpopulations of GABAergic (gamma-aminobutyric acidergic) interneurons. This developmentally regulated and cell type-specific expression pattern suggests that GluN2D contributes to the maturation and maintenance of excitatory-inhibitory balance and coordinated network activity. Although early progress in understanding GluN2D function was limited by a lack of selective tools and suitable models, recent breakthroughs in pharmacology, transgenic mouse models, and human genetic studies have significantly facilitated detailed investigations into the physiological and pathological roles of this subunit. In this review, we examine the unique physiological and pharmacological properties of GluN2D and underscore its growing significance in the context of neuropsychiatric and neurological disorders.

Indexed as

BrainReceptors, N-Methyl-D-AspartateAnimalsHumansReceptors, N-Methyl-D-AspartateCircuitsEpilepsyInterneuronsParkinson’s diseasePharmacologySchizophrenia

Identifiers

PMID41765344
PMCPMC13518594

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.